Matthew A. Powell
About
Matthew A. Powell is a scholar working on Obstetrics and Gynecology, Reproductive Medicine and Oncology.
According to data from OpenAlex, Matthew A. Powell has authored 170 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Obstetrics and Gynecology, 65 papers in Reproductive Medicine and 48 papers in Oncology. Recurrent topics in Matthew A. Powell's work include Endometrial and Cervical Cancer Treatments (91 papers), Ovarian cancer diagnosis and treatment (63 papers) and Cervical Cancer and HPV Research (27 papers). Matthew A. Powell is often cited by papers focused on Endometrial and Cervical Cancer Treatments (91 papers), Ovarian cancer diagnosis and treatment (63 papers) and Cervical Cancer and HPV Research (27 papers). Matthew A. Powell collaborates with scholars based in United States, Canada and Netherlands. Matthew A. Powell's co-authors include David G. Mutch, Janet S. Rader, Randall K. Gibb, Jason D. Wright, Perry W. Grigsby, Thomas J. Herzog, Barry A. Siegel, Farrokh Dehdashti, Premal H. Thaker and Perry W. Grigsby and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.
In The Last Decade
Matthew A. Powell
156 papers receiving 3.8k citations
Hit Papers
Peers
Matthew A. Powell
Myong Cheol Lim South Korea
Robert Giuntoli United States
Ritu Salani United States
Innocenza Palaia Italy
Cor D. de Kroon Netherlands
Sébastien Gouy France
Antonino Ditto Italy
Edward J. Tanner United States
Ali̇ Ayhan Türkiye
Bengt Sorbe Sweden
Citations per year, relative to Matthew A. Powell Matthew A. Powell (= 1×)
peers
Myong Cheol Lim
Countries citing papers authored by Matthew A. Powell
Since
Specialization
Citations
This map shows the geographic impact of Matthew A. Powell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew A. Powell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew A. Powell more than expected).
Fields of papers citing papers by Matthew A. Powell
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Matthew A. Powell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew A. Powell. The network helps show where Matthew A. Powell may publish in the future.
Co-authorship network of co-authors of Matthew A. Powell
This figure shows the co-authorship network connecting the top 25 collaborators of Matthew A. Powell. A scholar is included among the top collaborators of Matthew A. Powell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew A. Powell. Matthew A. Powell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Vergote, Ignace, David Cibula, Matthew A. Powell, et al.. (2025). Chemotherapy With Or Without Pembrolizumab Followed By Maintenance With Olaparib Or Placebo For First-Line Treatment Of Advanced BRCA Non-Mutated Epithelial Ovarian Cancer: Results From The Randomized Phase 3 ENGOT-OV43/GOG-3036/KEYLYNK-001 Study. International Journal of Gynecological Cancer. 35(2). 101704–101704.
2.
Thompson, Kevin, et al.. (2025). Clinical Images: Vasculitic rash as a presenting symptom of heparin‐induced thrombocytopenia in a woman with primary antiphospholipid syndrome. ACR Open Rheumatology. 7(2). e11793–e11793.
3.
Grither, Whitney R., David G. Mutch, Andrea R. Hagemann, et al.. (2024). Prophylactic antibiotics for excision of premalignant vulvar lesions: A pilot randomized controlled trial. Gynecologic Oncology Reports. 55. 101476–101476.
4.
Bogani, Giorgio, Bradley J. Monk, Matthew A. Powell, et al.. (2024). Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer. Annals of Oncology. 35(5). 414–428.
5.
Klopp, Ann H., Danielle Enserro, Matthew A. Powell, et al.. (2024). Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial. Journal of Clinical Oncology. 42(20). 2425–2435.
6.
Hagemann, Ian S., Sarah M. Temkin, Jessica N. McAlpine, et al.. (2024). Challenges in implementation of molecular classification in early stage endometrial cancer—An NRG Oncology cooperative group mixed‐methods study. Cancer. 131(1). e35596–e35596.
7.
Ghamande, Sharad, Lars Hanker, Destin Black, et al.. (2024). Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy among patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. Gynecologic Oncology. 190. S6–S6.
8.
Mirza, Mansoor Raza, Sudarshan Sharma, Jørn Herrstedt, et al.. (2023). 740MO Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. Annals of Oncology. 34. S507–S507.
9.
Slomovitz, Brian M., Robert L. Coleman, Lucy Gilbert, et al.. (2023). 750P PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial. Annals of Oncology. 34. S514–S515.
10.
Mirza, Mansoor Raza, Dana M. Chase, Brian M. Slomovitz, et al.. (2023). Dostarlimab in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: a placebo-controlled randomized phase 3 trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) (LBA 11). Gynecologic Oncology. 176. S43–S44.
11.
Rimel, B.J., Danielle Enserro, David Bender, et al.. (2023). NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer. 130(8). 1234–1245.
12.
Tanyi, János L., Leslie M. Randall, Setsuko K. Chambers, et al.. (2023). A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor–Positive Ovarian Cancer (Study 006). Obstetrical & Gynecological Survey. 78(6). 341–342.
13.
O’Cearbhaill, Roisin E., Michael W. Sill, Steven Waggoner, et al.. (2023). PO005LBA/#1579 A randomized, phase II/III study of pegylated-liposomal-doxorubicin and atezolizumab (IND #134427) versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-resistant ovarian cancer (NRG-GY009). A4–A4.
14.
Mirza, Mansoor Raza, Mark S. Shahin, Matthew A. Powell, et al.. (2023). Patient-reported outcomes (PROs) in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab (D) plus carboplatin/paclitaxel (CP) compared with CP in the ENGOT-EN6/GOG3031/RUBY trial.. JCO Oncology Practice. 19(11_suppl). 332–332.
15.
Powell, Matthew A., Virginia L. Filiaci, Martee L. Hensley, et al.. (2022). Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. Journal of Clinical Oncology. 40(9). 968–977.
16.
Cho, Kevin, Elena Lomonosova, Mary M. Mullen, et al.. (2022). GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis. Molecular Cancer Therapeutics. 21(8). 1348–1359.
17.
Huepenbecker, Sarah P., Lindsay M. Kuroki, Candice Woolfolk, et al.. (2019). Continuous epidural infusion in gynecologic oncology patients undergoing exploratory laparotomy: The new standard for decreased postoperative pain and opioid use. Gynecologic Oncology. 153(2). 356–361.
18.
Hagemann, Ian S., Lei Guo, Andrea R. Hagemann, et al.. (2017). Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer. Molecular Cancer Therapeutics. 16(12). 2881–2891.
19.
Novetsky, Akiva P., Lindsay M. Kuroki, L. Stewart Massad, et al.. (2013). The Utility and Management of Vaginal Cytology After Treatment for Endometrial Cancer. Obstetrics and Gynecology. 121(1). 129–135.
20.
Alleyne, Cargill H., Daniel L. Barrow, B. Poff, et al.. (1998). Efficacy and biocompatibility of a photopolymerized, synthetic, absorbable hydrogel as a dural sealant in a canine craniotomy model. Journal of neurosurgery. 88(2). 308–313.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Myong Cheol Lim Breakdown of academic impact, for papers by Robert Giuntoli Breakdown of academic impact, for papers by Ritu Salani Breakdown of academic impact, for papers by Innocenza Palaia Breakdown of academic impact, for papers by Cor D. de Kroon Breakdown of academic impact, for papers by Sébastien Gouy Breakdown of academic impact, for papers by Antonino Ditto Breakdown of academic impact, for papers by Edward J. Tanner Breakdown of academic impact, for papers by Ali̇ Ayhan Breakdown of academic impact, for papers by Bengt Sorbe